Immune, targeted therapy and related issues of relapsed/refractory multiple myeloma
10.3760/cma.j.cn371439-20200622-00074
- VernacularTitle:复发难治性多发性骨髓瘤的免疫靶向治疗及存在的问题
- Author:
Ruijie SUN
1
;
Ningning SHAN
Author Information
1. 山东大学附属省立医院 山东省立医院血液内科，济南 250021
- Keywords:
Multiple myeloma;
Molecular targeted therapy;
Immunotherapy
- From:
Journal of International Oncology
2021;48(6):381-384
- CountryChina
- Language:Chinese
-
Abstract:
The new immune and targeted therapy medicines of multiple myeloma and recurrence of refractory multiple myeloma mainly include immunomodulatory drugs, proteasome inhibitors, monoclonal antibody, immune monitoring point inhibitors, histone deacetylase and chimeric antigen receptor. Although the emergence of new drugs and the application of autologous hematopoietic stem cell transplantation have significantly improved the prognosis of patients, more effective treatment methods and treatment strategies are still required to deal with the adverse reactions and the condition of recurrence during treatment.
